An early safety test of a new drug for glioblastoma that came back
Original title: Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was an early safety test in people, not a test of whether it works.
The short version
A new drug was tested mainly for safety in people, and most side effects were mild.
What was studied. Doctors gave a new drug called LP-184 to 63 adults with advanced cancer. 16 of them had glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary that came back after standard treatment.
What they found. Overall the drug was well tolerated. Mild nausea was common, and severe low platelets or liver problems were rare. In mice, adding a second drug called spironolactone made LP-184 kill tumor twice as well.
What this means, and what it doesn't
What it could mean: The drug looks safe enough at this dose to keep testing in people. The team now has a plan to pair it with spironolactone in a later trial. This study does not tell us yet whether it helps people live longer.
What it doesn't mean: This is not a treatment you can get today. It was a first step safety study, not a test of whether the drug works. It did not show that tumors shrank or that people lived longer. The spironolactone part was done in mice, not people. This is not a cure, and it is not a promise of one.
Source: PubMed, October 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.